)
Zymeworks (ZYME) investor relations material
Zymeworks 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic transformation and business model evolution
Achieved a transformative year with positive HERIZON-GEA-01 data for zanidatamab, positioning it as a potential new standard of care in HER2-overexpressing GEA, replacing Herceptin.
Evolving strategy to leverage both innovative R&D and long-term royalty/milestone streams from assets like zanidatamab and pasritamig, creating a unique hybrid model in biotech.
Leadership and board changes implemented to align with the new strategic direction.
Strong financial foundation established, with a cash runway projected beyond 2028 and potential for excess cash flow.
Focus on compounding initial success into multiple value streams, including accessing external products and building a royalty portfolio.
Pipeline and R&D highlights
Zanidatamab demonstrated superior efficacy over trastuzumab in GEA, with robust PFS and OS data, and is advancing globally with partners Jazz and BeOne.
Pasritamig, a KLK2 T-cell engager with J&J, is in phase III and could represent a $1–5 billion peak sales opportunity.
Wholly owned pipeline includes promising ADCs and bispecifics, with upcoming data for folate receptor alpha ADC expected in 2026 and GPC3 ADC in early phase I.
IL-4 receptor alpha and IL-33 bispecifics represent first-in-class opportunities, with data anticipated after 2026.
Continued innovation in protein engineering and differentiated biologics remains central to the R&D approach.
Partnership and royalty strategy
Strategic partnerships with Jazz and BeOne have enabled global advancement and de-risking of key assets while retaining significant royalty and milestone upside.
Preference for holding royalty streams through key development milestones to maximize value, rather than early monetization.
Willingness to acquire additional high-quality royalty streams, especially where traditional royalty buyers avoid development risk.
Open to monetizing royalties if fair value is achieved, but current strategy is to retain and manage them for long-term shareholder benefit.
Partnership model allows for broad pipeline advancement without the need for an internal sales force.
Next Zymeworks earnings date
Next Zymeworks earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)